Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$17.88
-1.8%
$20.47
$10.21
$25.67
$4.35B0.433.70 million shs2.39 million shs
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$0.39
$0.39
$0.23
$2.83
$26.62M1.55943,490 shsN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
$0.40
$0.84
$0.34
$41.25
$1.18M0.46267,009 shs6,782 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.09
-9.5%
$7.21
$1.91
$11.64
$53.09M1.34736,887 shs8.75 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.12
+0.3%
$3.23
$2.65
$9.55
$172.10M0.85480,129 shs706,843 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+0.28%+1.90%-8.81%-6.23%+62.88%
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00%0.00%0.00%0.00%0.00%
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00%0.00%0.00%0.00%0.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
-56.66%-62.86%-69.03%-69.57%-73.81%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+5.07%+5.78%+14.34%-7.72%-60.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.0831 of 5 stars
3.72.00.00.02.72.53.1
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.1599 of 5 stars
0.00.00.03.80.60.00.0
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.6482 of 5 stars
3.40.00.00.02.11.70.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
4.0938 of 5 stars
3.61.00.04.62.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6754.74% Upside
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00
N/AN/AN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00
N/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.71
Moderate Buy$22.80990.91% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39329.17% Upside

Current Analyst Ratings Breakdown

Latest VYGR, ADMA, AXLA, INMB, and AGTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.01$0.53 per share33.64$1.48 per share12.08
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$320K83.19N/AN/A$0.26 per share1.51
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/A$1.42 per shareN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K4,802.82N/AN/A$1.45 per share1.44
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.16N/AN/A$5.49 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.0425.91N/A45.01%47.16%30.51%8/6/2025 (Estimated)
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
-$81.19M-$19.25N/AN/AN/AN/A-259.91%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest VYGR, ADMA, AXLA, INMB, and AGTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
N/AN/AN/AN/AN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.39
1.40
1.40
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/A
0.80
0.80
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
22.05%
Axcella Health Inc. stock logo
AXLA
Axcella Health
65.07%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million229.90 millionOptionable
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
8367.63 million64.86 millionOptionable
Axcella Health Inc. stock logo
AXLA
Axcella Health
112.95 million2.88 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.78 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million52.83 millionOptionable

Recent News About These Companies

VYGR Voyager Therapeutics, Inc. - Seeking Alpha
Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO
Voyager Announces Pricing of Initial Public Offering
Brokers Issue Forecasts for VYGR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$17.88 -0.33 (-1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$17.88 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Applied Genetic Technologies stock logo

Applied Genetic Technologies NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Axcella Health stock logo

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.09 -0.22 (-9.52%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 -0.01 (-0.53%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.12 +0.01 (+0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$3.10 -0.02 (-0.64%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.